Trinity Biotech

Trinity Biotech Altman Z-Score

The Altman Z-Score of Trinity Biotech (TRIB) as of Nov 10, 2026 is -1.44. In the previous year, Altman Z-Score was -1.09 — a change of 32.04% (lower).

Altman Z-Score

-1.44

YoY

32.04%

Last updated:

Altman Z-Score of Trinity Biotech is 2025 -1.44 . Altman Z-Score of Trinity Biotech was 2024 -1.09 . It decreases by 32.04% lower compared to the previous year.

The Trinity Biotech Altman Z-Score history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Altman Z-Score
Date
Altman Z-Score
Jan 1, 2018
1.02 USD
Jan 1, 2019
0.90 USD
Jan 1, 2020
0.96 USD
Jan 1, 2021
1.01 USD
Jan 1, 2022
-0.18 USD
Jan 1, 2023
-1.59 USD
Jan 1, 2024
-1.09 USD
Jan 1, 2025
-1.44 USD
The Trinity Biotech Altman Z-Score history
YEARAltman Z-ScoreYoY
-1.44+32.04%
-1.09-31.33%
-1.59+769.03%
-0.18-118.06%
1.01+5.13%
0.96+6.59%
0.90-11.42%
1.02+0.78%
1.01-6.41%
1.08-13.51%
1.25-34.97%
1.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Altman Z-Score of Trinity Biotech is -1.44 in 2025.

On Eulerpool you can find the complete historical development of Altman Z-Score Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The Altman Z-Score predicts bankruptcy probability using five financial ratios. Scores above 3.0 indicate safety, below 1.8 suggests distress risk.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Trinity Biotech

All Key Metrics — Trinity Biotech